Macrophage Depletion in Hypertensive Rats Accelerates Development of Cardiomyopathy by Zandbergen, H.R. et al.
 http://cpt.sagepub.com/
 
Therapeutics
Journal of Cardiovascular Pharmacology and
 http://cpt.sagepub.com/content/14/1/68
The online version of this article can be found at:
 
DOI: 10.1177/1074248408329860
 2009 14: 68 originally published online 22 January 2009J CARDIOVASC PHARMACOL THER
Pinto, Jagat Narula and Leo Hofstra
M.Pokharel, Thomas van Brakel, Adriaan Duijvestijn, Nico van Rooijen, Jos G. Maessen, Chris Reutelingsperger, Yigal 
Harmen R. Zandbergen, Umesh C. Sharma, Sudhir Gupta, Johan W. H. Verjans, Susanne van den Borne, Saraswati
Macrophage Depletion in Hypertensive Rats Accelerates Development of Cardiomyopathy
 
 
Published by:
 http://www.sagepublications.com
 can be found at:Journal of Cardiovascular Pharmacology and TherapeuticsAdditional services and information for 
 
 
 
 
 
 http://cpt.sagepub.com/cgi/alertsEmail Alerts: 
 
 http://cpt.sagepub.com/subscriptionsSubscriptions:  
 http://www.sagepub.com/journalsReprints.navReprints: 
 
 http://www.sagepub.com/journalsPermissions.navPermissions: 
 
 http://cpt.sagepub.com/content/14/1/68.refs.htmlCitations: 
 
 at Vrije Universiteit 34820 on November 23, 2010cpt.sagepub.comDownloaded from 
Macrophage Depletion in Hypertensive
Rats Accelerates Development of
Cardiomyopathy
Harmen R. Zandbergen, MD, Umesh C. Sharma, MD, PhD,
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Susanne van den Borne, MD, Saraswati Pokharel, MD, PhD,
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Nico van Rooijen, PhD, Jos G. Maessen, MD, PhD,
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Inflammation contributes to the process of ventricular
remodeling after acute myocardial injury. To inves-
tigate the role of macrophages in the chronic process
of cardiac remodeling, they were selectively depleted
by intravenous administration of liposomal clodronate
in heart failure–prone hypertensive Ren-2 rats from
the age of 7 until 13 weeks. Plain liposomes were used
for comparison. Liposomal clodronate treatment red-
uced the number of blood monocytes and decreased
the number of macrophages in the myocardium. Com-
pared to plain liposomes, liposomal clodronate treat-
ment rapidly worsened left ventricular ejection
function in hypertensive rats. Liposomal clodronate–
treated Ren-2 rat hearts showed areas of myocyte loss
with abundant inflammatory cell infiltration, predo-
minantly comprising CD4 positive T lymphocytes. The
current study showed that lack of macrophages was
associated with earlier development of myocardial
dysfunction in hypertensive rats. Modulation of
macrophage function may be of value in the evolution
of cardiomyopathy.
Keywords: hypertension; inflammation; ventricular
remodeling; heart failure
Introduction
Although inflammatory myocardial diseases are well
known to induce chronic cardiomyopathic state,
sparse inflammatory cell infiltration is commonly
observed in noninflammatory heart muscle dis-
ease.1,2 It is believed that inflammatory mechanisms
contribute to chronic cardiomyopathy by slow and
progressive tissue damage and alteration of myocar-
dial architecture or induction of autoimmunity.3,4
Macrophages may also contribute to myocardial dys-
function by producing inflammatory and profibrotic
mediators.5 Accumulating evidence on the patho-
physiological consequences of sustained expression
of macrophage-based proinflammatory mediators
in preclinical and clinical heart failure (HF) models
has led to several clinical trials that have used tar-
geted approaches to neutralize tumor necrosis
factor (TNF) in patients with moderate to advanced
HF.6,7 However, these targeted approaches have
not yielded the anticipated results. In the current
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study, we investigated the role of macrophages in
evolution of ventricular dysfunction in hypertensive
homozygous Ren-2 rats. These animals are known
to demonstrate rapid progression from hypertension
to compensated left ventricular hypertrophy and
HF. Male homozygous transgenic rats carrying 2
copies of mouse renin-2 genes (Ren-2 rats) exhibit
moderate hypertension, myocardial hypertrophy, and
excessive fibrosis associated with overproduction of
angiotensin-II (Ang-II). These pathological changes
can begin as early as 6 weeks of age and 50% of these
rats progress to HF by 12 to 14 weeks, while the other
half remain compensated at least till 17 weeks. The
failing Ren-2 rat hearts reveal abundant macrophage
infiltration.We hypothesized that antagonizingmacro-
phage influence in the heart by a depletion strategy
would result in a delay in the development of end-
stage hypertensive cardiomyopathy and HF. For this
purpose, we injected liposomal clodronate (LC) intra-
venously in homozygous Ren-2 rats, for selective elim-
ination of macrophages.8,9 Liposomal clodronate is
phagocytosed by circulating monocytes. Free clodro-
nate does not cross cell membranes and has an
extremely short half-life in the circulation. Liposomal
clodronate is removed from the circulation by the
renal system and has no major adverse effects on cell
types that do not phagocytose the liposomes.8-10
Methods
Experimental Design
Male, 6-week-old homozygous Ren-2 and Sprague
Dawley (SD) rats were obtained from M&B (Bom-
holtvej, Denmark). Clodronate was a gift from Roche
Diagnostics GmbH, Mannheim, Germany. Liposo-
mal clodronate and plain liposomes (PL) were pre-
pared as described previously.9 Under light
isoflurane anesthesia, 10 male homozygous Ren-2
rats received LC (4 mL/gram body weight) through
the tail vein, every week for 7 weeks. As a control for
the liposomally encapsulated clodronate, liposomes
filled with phosphate buffer saline (PBS) were
injected in 7 Ren-2 rats. In addition, 4 healthy SD
rats received LC and 4 age-matched SD rats received
PL. Rats were euthanized at 13 weeks. In all experi-
mental groups, blood pressure was measured by tail-
cuff method, and echocardiography was performed
at 0, 14, 28, and 42 days of LC or PL treatment in
rats sedated with 2% isoflurane. Standard views were
obtained in 2-dimensional as well as M-mode with a
12-MHz transducer (Sonos 5500, Hewlett Packard,
Netherlands) with approximately 220 frames per
recording and the data analysis was performed by a
blinded observer. The Institutional Animal Care and
Use Committee approved the procedure for care and
treatment of animals.
Peripheral Blood Monocytes and CD4þ
and CD8þ T cells
Peripheral blood monocytes and CD4þ and CD8þ T
cells were analyzed in Ren-2 rats at 2 and 7 days after
intravenous infusion of LC or PL with specific antibo-
dies by flow cytometry. In brief, anticoagulated blood
(200 mL) was incubated for 30 minutes (4C) with
mouse anti-rat R-phycoerythrin (RPE)-conjugated
anti-CD4, CD8, and CD68 antibodies (Serotec, Dus-
seldorf, Germany) and isotype controls. All analyses
were performed separately. Fluorescence-activated cell
sorting (FACS) lysing solution (1:20 dilution) was
added for 15 minutes. The residual cells were washed
(1500 rpm, 5 minutes, 4C) in FACSmedium (PBS,
1% bovine serum albumin [BSA], 0.02% sodium azide)
and suspended for flow cytometry.Monocytes and lym-
phocytes were identified according to their relative size,
side scattering, and fluorescence.
Immunohistochemical Localization of
Macrophages and T Lymphocytes in
Myocardium
Immunohistochemistry was performed on cryofixed
myocardial sections. After drying the sections for
15 minutes, ice-cold methanol (100%) was added
for 10 minutes; sections were washed 3 times with
PBS and blocked with 5% horse serum for 60 min-
utes. Anti-CD3, -CD4, -CD8, and -CD68 (Serotec)
and anti-annexin A5 (BioVision, Uithoorn, The
Netherlands) antibodies (1:250 in 0.1% BSA in PBS)
were applied and incubated overnight at 4C. Horse-
radish peroxidase–conjugated secondary antibodies
were then used for 4 hours at room temperature fol-
lowed by horseradish peroxidase–labeled streptavidin
for 60 minutes. After washing 3 times for 5 minutes
in PBS, 3,30-diaminobenzidine tetrahydrochloride
reagent was applied to visualize the reaction.
Statistical Analyses
Data are presented as mean + SD. The compari-
sons were made by unpaired t test. For multiple
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comparisons, 1-way analysis of variance (ANOVA) in
combination with a Dunnett’s post hoc analysis was
made. Analyses were performed by the use of the
statistical package SPSS 10.0. Probability value of
P < .05 was considered to be statistically significant.
Results
Peripheral Blood Monocyte Count and
the Interstitial Macrophage Infiltration
Baseline peripheral blood monocyte proportion in
PL-treated Ren-2 rats was 2.28% + 0.15% (Figure
1A and B). Two days after LC injection in Ren-2 rats,
the number of monocytes sharply reduced to 0.81%
+ 0.21% (Figure 1C and D), whereas CD4 and
CD8 count remained unchanged (CD4: LC, 43.6%
+ 3.5% vs. PL, 45 + 4.6; CD8: LC, 5% + 2.5%
vs. PL, 4.8 + 1.9, P ¼ NS; Table 1). However,
the monocyte count returned to baseline levels
(1.8 + 0.38) by 7 days. Presence of macrophages
in the hearts was shown byCD68-specific monoclonal
antibody. In the Ren-2 rats that received PL, macro-
phages were frequently observed (Table 2). However,
LC-treated Ren-2 rats showed scattered cells identical
to macrophage morphology; the macrophages also
stained positively for annexin A5, suggesting LC-
induced apoptotic changes in these cells (Figure 2A).
Annexin A5 positivity was not seen in the PL-treated
Ren-2 rats (Figure 2B) and control rats with LC
(Figure 2C) and PL (Figure 2D) treatment.
Evolution of Cardiac Function in
Monocyte-depleted Ren-2 Rats
The Ren-2 rats that received LC from 7 to 13 weeks
of age demonstrated significant deterioration of myo-
cardial function (ejection fraction (EF) %, baseline,
65.2 + 4.1; 6 weeks, 49 + 5.4, P < .05). However,
Ren-2 rats that received PL showed only a mild and
no decrease in cardiac performance (EF%, baseline,
Figure 1. Flow cytometric analysis of blood monocyte population after the infusion of LC or PL in Ren-2 rats. We injected PL or
LC in Ren-2 rats and collected the blood samples after 48 hours. Height of the histogram represents monocyte population. A, FACS
analysis of CD68 positive cells in the blood in PL-treated Ren-2 rats. B, Isotype control for panel A. C, CD68 positive cells in
LC-treated Ren-2 rats. D. Isotype control for panel C. FACS ¼ fluorescence-activated cell sorting; LC ¼ liposomal clodronate;
PL ¼ plain liposomes.
Table 1. Monocyte, CD4, and CD8 Count of
LC- and PL-treated Rats (%)a
Ren-2-LC Ren-2-PL
Monocytes 0.81 + 0.21 2.28 + 0.15
T-helper cells (CD4) 43.6 + 3.5 45+ 4.6
Cytotoxic T cells (CD8) 5 + 2.5 4.8 + 1.9
Abbreviations: LC, liposomal clodronate; PBS, phosphate buffer
saline; PL, PBS liposomes.
aP ¼ NS.
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67 + 3.1; 6 weeks, 62 + 5.3). The control rats did
not show any significant alteration in cardiac perfor-
mance, regardless of LC (EF%, baseline, 64 + 4;
6 weeks, 63 + 3.8) or PL (EF%, baseline, 65.5 +
1.9; 6 weeks, 66.4 + 1.0) administration (Table 3).
This suggests that persistent macrophage depletion
in hypertensive hearts (and normally with abundant
macrophage infiltration) accelerates functional dete-
rioration. There was no significant difference in body
weight between the 4 experimental groups. Ren-2 rats
were hypertensive and had significantly increased
heart weight to body weight ratio compared to
controls. However, these parameters were not signifi-
cantly different between LC- and PL-treated rats
(Table 4).
Histological Consequences of
Macrophage Depletion
The Ren-2 rats that received LC treatment for
6 weeks showed areas of cardiomyocyte damage
(Figure 3A), which was not discernible in control
groups (Figure 3B-D). Although there was a marked
decrease in number of macrophages, abundant focal
Table 2. Morphometric Data to Compare the Cellular Infiltration and Apoptotic Changes in the Myocardium of
LC- or PL-treated Rats
Cell counts/HPF
Ren-2-LC (N ¼ 7) Ren-2-PL (N ¼ 7) SD-LC (N ¼ 4) SD-PL (N ¼ 4)
Mononuclear cells (HE-staining) 89.3+ 26a 7 + 2.4 13.8 + 2.1 8.5 + 1
Macrophages (CD68) 1.8+ 0.31 13.8 + 3.3b 0.66 + 0.4 2.5 + 0.7
T-lymphocytes (CD3) 49+ 13.3a 3.3 + 0.68 4.8 + 1.1 4.3 + 0.8
T-helper cells (CD4) 33.8+ 13.7a 1.8 + 0.31 3.5 + 0.7 3.1 + 0.8
Cytotoxic T-cells (CD8) 2.8+ 0.4 2.3 + 0.50 2.1 + 0.4 2.3 + 0.51
Apoptotic cells (Annexin A5) 10.5+ 4.2a 2.1 + 0.66 3.1 + 0.7 1.1 + 0.4
Abbreviations: HE, hematoxylin-eosin; HPF, high power field; LC, liposomal clodronate; PBS, phosphate buffer saline; PL, PBS
liposomes; SD, Sprague Dawley.
aP < .05 versus Ren-2-PL, SD-LC, and SD-PL.
bP < .05 versus Ren-2-LC, SD-LC, and SD-PL.
Figure 2. Demonstration of apoptosis-specific changes by annexin A5 positivity. A, Anti-annexin A5 staining showing apoptosis
of macrophages in LC-treated Ren-2 rat hearts. B-D, Anti-annexin A5 staining in PL-treated Ren-2 rats, LC-treated SD rats, and
PL-treated SD rats, respectively. LC ¼ liposomal clodronate; PL ¼ plain liposomes; SD ¼ Sprague Dawley.
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Table 3. Baseline, 2-,4-, and 6-Week Echocardiographic Parameters in LC- or PL-treated Ren-2 Rats and
SD Controls
LV Functional Parameters Time Point Ren-2-LC (N ¼ 10) Ren-2-PL (N ¼ 7) SD-LC (N ¼ 4) SD-PL (N ¼ 4)
EF (%) Baseline 65.2 + 4.1 67 + 3.1 64+ 4 65.5 + 1.9
2 weeks 64.6 + 4.9 66.9 + 3.04 63.3 + 3.4 63.7 + 2.7
4 weeks 57+ 6.6 64.3 + 6.4 62.6 + 2.3 64.5 + 3.9
6 weeks 49+ 5.4a 62 + 5.3 63+ 3.8 66.4 + 1.0
FS (%) Baseline 32.7 + 4.2 34.8 + 4.2 31.2 + 3.8 36.7 + 0.5
2 weeks 30+ 4 30.2 + 4 30.2 + 1.5 35.2 + 1.2
4 weeks 26+ 3.2 26.5 + 3.2 28.5 + 3.7 34.2 + 2.2
6 weeks 22.8 + 4.8a 30.2 + 4.2 30.7 + 3.5 34.4 + 3.2
EDV (mL) Baseline 0.41 + 0.26 0.40 + 0.17 0.44 + 0.15 0.40 + 0.07
2 weeks 0.55 + 0.21 0.41 + 0.16 0.41 + 0.1 0.4 + 0.05
4 weeks 0.81 + 0.35 0.43 + 0.09 0.41 + 0.07 0.4 + 0.06
6 weeks 1.1+ 0.68a 0.43 + 0.16 0.42 + 0.03 0.42 + 0.07
Abbreviations: EF, LV ejection fraction; EDV, end diastolic volume; FS, LV fractional shortening; LC, liposomal clodronate; LV, left
ventricular; PBS, phosphate buffer saline; PL, PBS liposome; SD, Sprague Dawley.
aP < .05 versus Ren-2 placebo and SD rats.
Table 4. Blood Pressure, Heart Weight, and Body Weight of LC- and PL-treated Rats
Ren-2-LC (N ¼ 7) Ren-2-PL (N ¼ 7) SD-LC (N ¼ 4) SD-PL (N ¼ 4)
BP (mm Hg) 253+ 15a 259+ 10a 131+ 4.7 128 + 10
BW (g) 314+ 18 310+ 23 314+ 13.5 308 + 8.9
HW/BW (%) 0.47 + 0.04a 0.50+ 0.05a 0.36 + 0.03 0.35 + 0.03
Abbreviations: BP, blood pressure; BW, body weight; HW/BW, heart weight to body weight ratio; LC, liposomal clodronate;
PBS, phosphate buffer saline; PL, PBS liposomes; SD, Sprague Dawley.
aP < .05 versus SD-LC and SD-PL.
Figure 3. Histological characterization of the myocardial changes in LC-treated Ren-2 rats and controls. A, Hematoxylin-eosin
stained myocardial sections showed areas of cardiomyocyte damage with mononuclear cellular infiltration in LC-treated Ren-2 rats.
These changes were not remarkable in PL-treated Ren-2 (panel B), LC-treated SD (panel C), and PL-treated SD (panel D) rat hearts.
LC ¼ liposomal clodronate; PL ¼ plain liposomes; SD ¼ Sprague Dawley.
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infiltrates of mononuclear cells were noted in the
myocardium in LC-treated Ren-2 rat hearts. Mor-
phologically, the infiltrated cells showed round
nucleus with myocardial interstitial pattern of dis-
tribution (Figure 3A). Immunohistochemical analy-
sis revealed that these round cells expressed CD3
(Figure 4) and CD4 antigen, suggesting that the
macrophage-depleted Ren-2 rat hearts harbor
increased CD4þ T-helper cells in the myocardium
(Table 2).
Discussion
In contrast to our beginning hypothesis, the results
of the current study suggest that the depletion of
macrophages, in a model of hypertensive heart dis-
ease, results in the accelerated development of
end-stage hypertensive cardiomyopathy and HF. The
macrophage-depleted hearts showed infiltration
with CD4þ T lymphocyte and multifocal loss of
cardiomyocytes.
The possible role of macrophage infiltration in
cardiomyopathy can be discussed as follows. First,
minimal fibrosis was demonstrated and neither
fibroblasts nor collagen deposition was observed. It
is known that macrophage-related cytokines
are associated with myofibroblast proliferation and
collagen production. Although development of inter-
stitial fibrosis is an important component of
cardiomyopathic process, it is reasonable to observe
that complete abolition of fibrosis should be detri-
mental. In a postinfarction model, macrophage
depletion has been reported to be associated with
acute ventricular dilatation and early onset of
HF.11 It has also been demonstrated that intramyo-
cardial injection of collagen prevents ventricular
aneurysmal formation and HF.12 Although these
experiments highlight the importance of the collagen
framework in healing from myocardial injury,
neurohumoral antagonists (which have proven to
be effective in prevention of remodeling and longev-
ity) are known to reduce collagen deposition.13 It is
therefore likely that both excessive collagen deposi-
tion as well as lack of collagen deposit is adversorial
in myocardial remodeling. Second, cardiomyopa-
thies are associated with increased circulating
levels of various cytokines, including TNF-a, which
are known to be detrimental for myocardial func-
tion.14 However, blocking of TNF-a has paradoxi-
cally resulted in worsening of experimental chronic
Chagas disease–mediated cardiomyopathy,15 which
is similar to our observations. Third, macrophage-
depleted hearts showed abundant T-lymphocyte
infiltration. The mechanisms for compensatory
CD4þ T-cell infiltration in macrophage-depleted
Figure 4. Demonstration of T-lymphocyte infiltration in LC-treated Ren-2 rat hearts. A, Anti-CD3 staining showing abundance
of T lymphocytes in the hearts of Ren-2-rats treated with LC. B-D, Anti-CD3 staining in PL-treated Ren-2, LC-treated SD, and
PL-treated SD rat hearts, respectively.
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hypertensive rats remain unclear. At least 4 distinct
subsets of CD4þ T cells have been recognized
including Th1, Th2, Treg, and Th17 cells. Treg
appear to play a protective role16 and Th2 cells play
a role in antibody-mediated response; as such
CD4þ T cells in our study are unlikely to be Treg
or Th2 cells. Therefore, we assume that the CD4þ
T-cell infiltrates may be composed of either Th1
cells, Th17 cells, or both. Th17 cells secrete a num-
ber of proinflammatory cytokines, including inter-
leukin (IL)-17, and have shown to play an
important role in autoimmunity and inflamma-
tion.17-19 It has been shown that IL-7-mediates
experimental autoimmune cardiomyopathy in t-bet
knock out mice (t-bet favors Th1 development),
suggesting a role of IL-17 in cardiomyopathy.20
Taken together, sustained depletion of macro-
phages could contribute to the deterioration of car-
diac function because of the loss of the beneficial
aspects of macrophage function and/or deleterious
effects of enhanced CD4þ T-cell infiltration.
Conclusions
The results of the current study show a potentially
important role of macrophages in ventricular remo-
deling in hypertension. Macrophage activation may
be important in repair processes and debris clear-
ance and hence depletion of macrophages may not
necessarily be an effective strategy in prevention of
HF. However, larger studies may be needed to eval-
uate the role of modest modulation of macrophage
function.
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